Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same

A fusion protein comprising a fibroblast growth factor 21 (FGF21) mutant protein and an Fc region of an immunoglobulin,

• wherein the FGF21 mutant protein comprises one mutation selected from the group consisting of the following mutations (a)-(e):
• (a) a substitution of the amino acids at positions 98 to 101 from the N-terminus of a wild-type FGF21 protein with the amino acid sequence of EIRP (SEQ ID NO:
• 42);
• (b) a substitution of the amino acids at positions 170 to 174 from the N-terminus of a wild-type FGF21 protein with the amino acid sequence of TGLEAV (SEQ ID NO:
• 43);
• (c) a substitution of the amino acids at positions 170 to 174 from the N-terminus of a wild-type FGF21 protein with the amino acid sequence of TGLEAN (SEQ ID NO:
• 44);
• (d) a substitution of the amino acid at position 174 from the N-terminus of a wild-type FGF21 protein with the amino acid N;
• and
• (e) a combination of the (a) and (b), a combination of the (a) and (c), or a combination of the (a) and (d), and
• wherein the wild-type FGF21 protein in (a)-(d) comprises the amino acid sequence of SEQ ID NO:
• 1.